Hologic, Inc. (NASDAQ:HOLX) Director Elaine Ullian sold 8,849 shares of the firm’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $45.28, for a total value of $400,682.72. Following the completion of the transaction, the director now directly owns 23,810 shares in the company, valued at approximately $1,078,116.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Elaine Ullian also recently made the following trade(s):

  • On Friday, June 2nd, Elaine Ullian sold 8,938 shares of Hologic stock. The stock was sold at an average price of $43.99, for a total value of $393,182.62.

Shares of Hologic, Inc. (HOLX) traded down 1.26% during mid-day trading on Thursday, reaching $44.59. The company had a trading volume of 2,669,955 shares. The stock has a 50 day moving average of $44.35 and a 200-day moving average of $42.22. Hologic, Inc. has a 52 week low of $33.67 and a 52 week high of $46.80. The company has a market capitalization of $12.49 billion, a price-to-earnings ratio of 15.99 and a beta of 0.91.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, May 10th. The medical equipment provider reported $0.50 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.04. Hologic had a return on equity of 25.26% and a net margin of 27.31%. The business had revenue of $715.40 million during the quarter, compared to analysts’ expectations of $685.24 million. During the same quarter in the prior year, the firm earned $0.47 earnings per share. The business’s revenue was up 3.2% compared to the same quarter last year. On average, analysts expect that Hologic, Inc. will post $2.01 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Insider Selling: Hologic, Inc. (HOLX) Director Sells 8,849 Shares of Stock” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/07/06/insider-selling-hologic-inc-holx-director-sells-8849-shares-of-stock.html.

Several large investors have recently bought and sold shares of HOLX. State Street Corp boosted its stake in Hologic by 1.5% in the first quarter. State Street Corp now owns 12,710,718 shares of the medical equipment provider’s stock valued at $540,846,000 after buying an additional 189,572 shares in the last quarter. Victory Capital Management Inc. boosted its stake in Hologic by 418.5% in the first quarter. Victory Capital Management Inc. now owns 4,050,824 shares of the medical equipment provider’s stock valued at $172,363,000 after buying an additional 3,269,503 shares in the last quarter. Bank of Montreal Can boosted its stake in Hologic by 67.8% in the first quarter. Bank of Montreal Can now owns 3,206,769 shares of the medical equipment provider’s stock valued at $136,448,000 after buying an additional 1,295,885 shares in the last quarter. American Century Companies Inc. boosted its stake in Hologic by 229.4% in the first quarter. American Century Companies Inc. now owns 3,164,928 shares of the medical equipment provider’s stock valued at $134,668,000 after buying an additional 2,204,085 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Hologic by 6.4% in the first quarter. Geode Capital Management LLC now owns 3,116,366 shares of the medical equipment provider’s stock valued at $132,440,000 after buying an additional 186,854 shares in the last quarter. 94.47% of the stock is owned by hedge funds and other institutional investors.

Several research analysts have recently commented on the company. Jefferies Group LLC reaffirmed a “buy” rating and issued a $49.00 price objective on shares of Hologic in a research note on Wednesday, June 28th. Zacks Investment Research downgraded Hologic from a “buy” rating to a “hold” rating in a research note on Tuesday, May 23rd. Leerink Swann reaffirmed an “outperform” rating and issued a $52.00 price objective on shares of Hologic in a research note on Thursday, March 30th. Needham & Company LLC raised their price objective on Hologic from $46.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, April 4th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $51.00 price objective on shares of Hologic in a research note on Tuesday, March 14th. Five analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $47.54.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Insider Buying and Selling by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.